CoChat
Sign Up
Cited by 58Bacterial Infections and VaccinesImmune responses and vaccinationsImmunotherapy and Immune Responses

The DOI matches its Crossref record; the references it cites are not checked yet.

The influence of carrier protein on the immunogenicity of simultaneously administered conjugate vaccines in infants

Pöllabauer, Eva Maria, Petermann, Robert, Ehrlich, Hartmut J.·2009·Vaccine
DOI 10.1016/j.vaccine.2009.01.005
Open this paper in CoChat — free account

Abstract

Continuing additions of new vaccines to routine infant vaccination schedules have prompted concerns about potential interactions between vaccine components reducing desired protective effects. One hypothesis is that increasing loads of carrier protein may interfere with immune responses to polysaccharide components of co-administered glycoconjugate vaccines. Based upon a critical appraisal of existing evidence, however, neither carrier protein type nor dose adequately explains observed interference. Moreover, in five clinical trials, enhancement of anti-polyribosylribitol phosphate Haemophilus influenzae type b antibody has been demonstrated after co-administration of monovalent meningococcal C conjugate vaccine with tetanus toxoid carrier. Empirical observations do not fit well with carrier-induced epitope suppression as an underlying mechanism of interference. Thus, co-administration of conjugate vaccines can have positive as well as negative effects, and predictors of vaccine interactions are still lacking.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.vaccine.2009.01.005

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

The citation lists haven’t been fetched yet

References 53 · Cited by 58

Research works printed but not linked: 51

  1. Clemens, 1995, Interactions between PRP-T vaccine against Haemophilus influenzae type b and conventional infant vaccines. Lessons for future studies of simultaneous immunization and combined vaccines, Ann N Y Acad Sci, 754, 255, 10.1111/j.1749-6632.1995.tb44458.x · DOI
  2. Buttery, 2005, Immunogenicity and safety of a combination pneumococcal-meningococcal vaccine in infants: a randomized controlled trial, JAMA, 293, 1751, 10.1001/jama.293.14.1751 · DOI
  3. Finn, 2005, Conjugate vaccines, Arch Dis Child, 90, 667, 10.1136/adc.2005.072173 · DOI
  4. Pöllabauer, 2005, Group C meningococcal polysaccharide-tetanus toxoid conjugate vaccine: a meta-analysis of immunogenicity, safety and posology, Hum Vaccin, 1, 131, 10.4161/hv.1.4.2018 · DOI
  5. Galizia, 2007, Pneumococcal conjugate vaccines. A review, Minerva Med, 98, 131
  6. Makwana, 2007, Bacterial meningitis: the impact of vaccination, CNS Drugs, 21, 355, 10.2165/00023210-200721050-00001 · DOI
  7. Finn, 2004, Bacterial polysaccharide–protein conjugate vaccines, Br Med Bull, 70, 1, 10.1093/bmb/ldh021 · DOI
  8. Dagan, 1998, Reduced response to multiple vaccines sharing common protein epitopes that are administered simultaneously to infants, Infect Immun, 66, 2093, 10.1128/IAI.66.5.2093-2098.1998 · DOI · Paper page
  9. Dagan, 2004, Reduction of antibody response to an 11-valent pneumococcal vaccine coadministered with a vaccine containing acellular pertussis components, Infect Immun, 72, 5383, 10.1128/IAI.72.9.5383-5391.2004 · DOI
  10. Heath, 2002, The UK Hib vaccine experience, Arch Dis Child, 86, 396, 10.1136/adc.86.6.396 · DOI
  11. McVernon, 2003, Risk of vaccine failure after Haemophilus influenzae type b (Hib) combination vaccines with acellular pertussis, Lancet, 361, 1521, 10.1016/S0140-6736(03)13171-6 · DOI
  12. Dagan, 2008, Combination vaccines containing DTPa-Hib: impact of IPV and coadministration of CRM197 conjugates, Expert Rev Vaccines, 7, 97, 10.1586/14760584.7.1.97 · DOI
  13. Trotter, 2003, Rising incidence of Haemophilus influenzae type b disease in England and Wales indicates a need for a second catch-up vaccination campaign, Commun Dis Public Health, 6, 55
  14. Pollard, 2007, New combination vaccines still need a boost, Arch Dis Child, 92, 1, 10.1136/adc.2006.106724 · DOI
  15. Eskola, 1996, Randomised trial of the effect of co-administration with acellular pertussis DTP vaccine on immunogenicity of Haemophilus influenzae type b conjugate vaccine, Lancet, 348, 1688, 10.1016/S0140-6736(96)04356-5 · DOI
  16. Pichichero, 1997, Vaccine antigen interactions after a combination diphtheria-tetanus toxoid-acellular pertussis/purified capsular polysaccharide of Haemophilus influenzae type b-tetanus toxoid vaccine in two-, four- and six-month-old infants, Pediatr Infect Dis J, 16, 863, 10.1097/00006454-199709000-00009 · DOI
  17. Schmitt, 1998, Immunogenicity and reactogenicity of a Haemophilus influenzae type b tetanus conjugate vaccine when administered separately or mixed with concomitant diphtheria-tetanus-toxoid and acellular pertussis vaccine for primary and for booster immunizations, Eur J Pediatr, 157, 208, 10.1007/s004310050797 · DOI
  18. Kitchin, 2007, Evaluation of a diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae type b vaccine given concurrently with meningococcal group C conjugate vaccine at 2, 3 and 4 months of age, Arch Dis Child, 92, 11, 10.1136/adc.2005.076109 · DOI
  19. Bell, 1998, Effect of combination with an acellular pertussis, diphtheria, tetanus vaccine on antibody response to Hib vaccine (PRP-T), Vaccine, 16, 637, 10.1016/S0264-410X(97)84511-2 · DOI
  20. Eskola, 1999, Combined vaccination of Haemophilus influenzae type b conjugate and diphtheria-tetanus-pertussis containing acellular pertussis, Lancet, 354, 2063, 10.1016/S0140-6736(99)04377-9 · DOI
  21. Decker, 2000, Combination vaccines: problems and promise, J Pediatr, 137, 291, 10.1067/mpd.2000.109026 · DOI
  22. Daum, 2001, Magnitude of interference after diphtheria-tetanus toxoids-acellular pertussis/Haemophilus influenzae type b capsular polysaccharide-tetanus vaccination is related to the number of doses administered, J Infect Dis, 184, 1293, 10.1086/324007 · DOI
  23. Poolman, 2001, Clinical relevance of lower Hib response in DTPa-based combination vaccines, Vaccine, 19, 2280, 10.1016/S0264-410X(00)00517-X · DOI
  24. Johnson, 2006, Haemophilus influenzae type b reemergence after combination immunization, Emerg Infect Dis, 12, 937, 10.3201/eid1206.051451 · DOI
  25. Rennels, 2000, Diminution of the anti-polyribosylribitol phosphate response to a combined diphtheria-tetanus-acellular pertussis/Haemophilus influenzae type b vaccine by concurrent inactivated poliovirus vaccination, Pediatr Infect Dis J, 19, 417, 10.1097/00006454-200005000-00006 · DOI
  26. Carlsson, 1999, Studies on a Hib-tetanus toxoid conjugate vaccine: effects of co-administered tetanus toxoid vaccine, of administration route and of combined administration with an inactivated polio vaccine, Vaccine, 18, 468, 10.1016/S0264-410X(99)00238-8 · DOI
  27. Oosterhuis-Kafeja, 2007, Immunogenicity, efficacy, safety and effectiveness of pneumococcal conjugate vaccines (1998–2006), Vaccine, 25, 2194, 10.1016/j.vaccine.2006.11.032 · DOI
  28. Decker, 1992, Comparative trial in infants of four conjugate Haemophilus influenzae type b vaccines, J Pediatr, 120, 184, 10.1016/S0022-3476(05)80424-X · DOI
  29. Ada, 2003, Carbohydrate–protein conjugate vaccines, Clin Microbiol Infect, 9, 79, 10.1046/j.1469-0691.2003.00530.x · DOI
  30. Scott, 2008, Phase 1 trial of 13-valent pneumococcal conjugate vaccine in Japanese adults, Pediatr Int, 50, 295, 10.1111/j.1442-200X.2008.02593.x · DOI
  31. Richmond, 2001, Evaluation of de-O-acetylated meningococcal C polysaccharide-tetanus toxoid conjugate vaccine in infancy: reactogenicity, immunogenicity, immunologic priming, and bactericidal activity against O-acetylated and de-O-acetylated serogroup C strains, Infect Immun, 69, 2378, 10.1128/IAI.69.4.2378-2382.2001 · DOI
  32. Kitchin, 2006, Vaccine, 24, 3964, 10.1016/j.vaccine.2006.02.018 · DOI
  33. Southern, 2006, Immunogenicity of one, two or three doses of a meningococcal C conjugate vaccine conjugated to tetanus toxoid, given as a three-dose primary vaccination course in UK infants at 2, 3 and 4 months of age with acellular pertussis-containing DTP/Hib vaccine, Vaccine, 24, 215, 10.1016/j.vaccine.2005.07.060 · DOI
  34. Tejedor, 2006, Pediatr Infect Dis J, 25, 713, 10.1097/01.inf.0000227725.61495.c4 · DOI
  35. Schmitt, 2007, Immunogenicity, reactogenicity, and immune memory after primary vaccination with a novel Haemophilus influenzae-Neisseria meningitidis serogroup C conjugate vaccine, Clin Vaccine Immunol, 14, 426, 10.1128/CVI.00377-06 · DOI
  36. Gatchalian, 2008, The development of a new heptavalent diphtheria-tetanus-whole cell pertussis-hepatitis B-Haemophilus influenzae type b-Neisseria meningitidis serogroups A and C vaccine: a randomized dose-ranging trial of the conjugate vaccine components, Int J Infect Dis, 12, 278, 10.1016/j.ijid.2007.08.007 · DOI
  37. English, 2000, A randomised, double-blind, controlled trial of the immunogenicity and tolerability of a meningococcal group C conjugate vaccine in young British infants, Vaccine, 19, 1232, 10.1016/S0264-410X(00)00241-3 · DOI
  38. Granoff, 1993, Effect of immunity to the carrier protein on antibody responses to Haemophilus influenzae type b conjugate vaccines, Vaccine, 11, S46, 10.1016/0264-410X(93)90160-Y · DOI
  39. Castillo de Febres, 1994, Enhanced antibody response in Venezuelan infants immunized with Haemophilus influenzae type b-tetanus toxoid conjugate vaccine, Pediatr Infect Dis J, 13, 635, 10.1097/00006454-199407000-00010 · DOI
  40. Granoff, 1994, Effect of carrier protein priming on antibody responses to Haemophilus influenzae type b conjugate vaccines in infants, JAMA, 272, 1116, 10.1001/jama.272.14.1116 · DOI
  41. Kurikka, 1996, Priming with diphtheria-tetanus-pertussis vaccine enhances the response to the Haemophilus influenzae type b tetanus conjugate vaccine in infancy, Vaccine, 14, 1239, 10.1016/S0264-410X(96)00025-4 · DOI
  42. Goldblatt, 2006, Immunogenicity and boosting after a reduced number of doses of a pneumococcal conjugate vaccine in infants and toddlers, Pediatr Infect Dis J, 25, 312, 10.1097/01.inf.0000207483.60267.e7 · DOI
  43. Tejedor, 2007, Pediatr Infect Dis J, 26, 1, 10.1097/01.inf.0000247070.60063.09 · DOI
  44. Insel, 1995, Potential alterations in immunogenicity by combining or simultaneously administering vaccine components, Ann N Y Acad Sci, 754, 35, 10.1111/j.1749-6632.1995.tb44436.x · DOI
  45. Herzenberg, 1980, Carrier-priming leads to hapten-specific suppression, Nature, 285, 664, 10.1038/285664a0 · DOI
  46. Schutze, 1989, Carrier-induced epitopic suppression is initiated through clonal dominance, J Immunol, 142, 2635, 10.4049/jimmunol.142.8.2635 · DOI
  47. Renjifo, 1998, Carrier-induced, hapten-specific suppression: a problem of antigen presentation?, J Immunol, 161, 702, 10.4049/jimmunol.161.2.702 · DOI
  48. Herzenberg, 1982, Epitope-specific regulation. I. Carrier-specific induction of suppression for IgG anti-hapten antibody responses, J Exp Med, 155, 1730, 10.1084/jem.155.6.1730 · DOI
  49. Peeters, 1991, Effect of carrier priming on immunogenicity of saccharide–protein conjugate vaccines, Infect Immun, 59, 3504, 10.1128/IAI.59.10.3504-3510.1991 · DOI · Paper page
  50. Di John, 1989, Effect of priming with carrier on response to conjugate vaccine, Lancet, 2, 1415, 10.1016/S0140-6736(89)92033-3 · DOI
  51. Redhead, 1994, Interaction of Haemophilus influenzae type b conjugate vaccines with diphtheria-tetanus-pertussis vaccine in control tests, Vaccine, 12, 1460, 10.1016/0264-410X(94)90156-2 · DOI

Metadata

Authors
Pöllabauer, E. M., Petermann, R., & Ehrlich, H. J.
Affiliations
Baxter (Austria) (AT)
Corresponding author
Pöllabauer, Eva Maria
ORCID
Ehrlich, Hartmut J.
Venue
Vaccine
Publisher
Elsevier BV
Published
2009-03
Volume
27
Issue
11
Pages
1674-1679
ISSN
0264-410X (ISSN-L)
DOI
10.1016/j.vaccine.2009.01.005
OpenAlex
W2079081917
Cited by
58
References
53
Citations by year
2026: 3 · 2024: 3 · 2023: 3 · 2021: 6 · 2020: 1 · 2019: 3 · 2018: 6 · 2017: 3 · 2016: 3 · 2015: 5 · 2014: 4 · 2013: 1 · 2012: 3
FWCI
0.67
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Vaccine (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Immunology and Microbiology › Microbiology › Bacterial Infections and Vaccines
  • Life Sciences › Immunology and Microbiology › Immunology › Immune responses and vaccinations
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
carrier proteins, glycoconjugate vaccines, polysaccharide vaccine, Haemophilus influenzae type b, meningococcal C vaccine, infant immunization, immunogenicity
MeSH terms
Antibodies, Bacterial, Epitopes, Carrier Proteins, Humans, Infant, Infant, Newborn, Tetanus Toxoid, Haemophilus Vaccines, Vaccines, Conjugate, Haemophilus influenzae type b, Neisseria meningitidis, Serogroup C

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review